Literature DB >> 3735272

Cancer mortality in patients with rheumatoid arthritis.

M Laakso, O Mutru, H Isomäki, K Koota.   

Abstract

Patients with rheumatoid arthritis (RA), 500 males and 500 females, aged 40 years and over, together with an age and sex matched control population, were observed over a 10-year period. The overall mortality was significantly higher in both men and women with RA than in the controls. During the followup, 42 patients with RA (28 males, 14 females) and 58 control subjects (36 males, 22 females) died from malignant neoplasms, but this difference was not statistically significant. A significant excess of deaths from neoplasms of the hematopoietic system was observed in patients with RA. Subjects without RA had significantly higher mortality rate from cancer of gastrointestinal origin than patients with RA.

Entities:  

Mesh:

Year:  1986        PMID: 3735272

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  6 in total

1.  Acute myelogenous leukemia in a rheumatoid arthritis patient under cyclosporine A therapy.

Authors:  P Casoli; B Tumiati
Journal:  Clin Rheumatol       Date:  1994-12       Impact factor: 2.980

Review 2.  Safety aspects of cyclosporin in rheumatoid arthritis.

Authors:  B A Dijkmans
Journal:  Drugs       Date:  1995       Impact factor: 9.546

3.  Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-delta in human endometrial adenocarcinoma.

Authors:  B J Tong; J Tan; L Tajeda; S K Das; J A Chapman; R N DuBois; S K Dey
Journal:  Neoplasia       Date:  2000 Nov-Dec       Impact factor: 5.715

Review 4.  [Epidemiological studies for evaluating the role of cyclooxygenase in chemoprevention of malignant tumors].

Authors:  Eva S Schernhammer; Christian Dittrich
Journal:  Wien Med Wochenschr       Date:  2003

5.  Mortality in patients with rheumatoid arthritis treated actively from the time of diagnosis.

Authors:  R Peltomaa; L Paimela; H Kautiainen; M Leirisalo-Repo
Journal:  Ann Rheum Dis       Date:  2002-10       Impact factor: 19.103

Review 6.  A risk-benefit assessment of slow-acting antirheumatic drugs in rheumatoid arthritis.

Authors:  A A Kalla; A F Tooke; E Bhettay; O L Meyers
Journal:  Drug Saf       Date:  1994-07       Impact factor: 5.606

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.